Erwei Song
Position not listed
Peking University · Beijing
Source
OpenAlexVerification
Academic database source — not independently verified
On file
- Not publicly verified
- ORCID
- 0000-0002-5400-9049
- Lab or group
- Not publicly verified
- Supervision
- Not publicly verified
- Last updated
- 2026-10-05
Research areas
Research interests
MicroRNA in disease regulation, Cancer-related molecular mechanisms research, Cancer Cells and Metastasis, RNA Interference and Gene Delivery, Cancer Immunotherapy and Biomarkers
Funding
Unknown
Not publicly verified. No grant, project, or funded-student record is stored.
Research timeline
Newest stored year: 2026. Topics on file: MicroRNA in disease regulation, Cancer-related molecular mechanisms research, Cancer Cells and Metastasis, RNA Interference and Gene Delivery, Cancer Immunotherapy and Biomarkers.
2026
- A multi-centre, phase 1a/1b dose escalation and expansion study of the HER2-directed antibody–drug conjugate T-Bren (BL-M07D1) in advanced breast cancer and other solid tumours (2026)
- Comparative outcomes of conventional versus endoscopic-assisted surgery for breast phyllodes tumors: a single center retrospective cohort study (2026)
- Neoadjuvant Pertuzumab Biosimilar HLX11 Versus Reference Pertuzumab for Early-stage or Locally Advanced Breast Cancer: A phase 3 Equivalence Trial (2026)
- Neutrophil extracellular traps promote liver metastasis by impairing NK cell-dependent tumor surveillance via CCDC25 (2026)
- Trastuzumab rezetecan versus pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer (HORIZON-Breast01): interim analysis of a multicentre, open-label, randomised, controlled, phase 3 trial (2026)
Papers linked only by a name match stay hidden.
Research match score
Sign in to see your personalized research match.
Target: Low priority
- Research fit is not included until you sign in and save research interests.
- Affiliation is not verified.
- No email is stored.
- A stored publication year is 2026.
- Funding evidence is unknown, so it does not raise the priority.
Match, then draft, then copy. Mark Contacted on the tracker. Follow up only after you send it yourself.
Sign in